Ardent HealthvsJohnson & Johnson

ARDT and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

ARDT

Ardent Health, Inc.

$14.50

Value $2.1B

+0.69%
ARDT's page

Ardent Health (ARDT) has a market value of $2.1B and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, ARDT moved +66.7% and JNJ +36.6%. The P/E is 14.2 for ARDT and 40.0 for JNJ. Dividend yield: ARDT none, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ARDT$2.1B

    JNJ$644B

    JNJ is 311 times ARDT

  • Revenue, 12 months

    ARDT$6.5B

    JNJ$99.3B

    JNJ is 15 times ARDT

  • Net income, 12 months

    ARDT$146M

    JNJ$16.1B

    JNJ is 110 times ARDT

  • Operating margin

    ARDT–

    JNJ–

  • ROIC

    ARDT9.5%

    JNJ12.4%

    2.9 points apart

  • P/E

    ARDT14.2

    JNJ40.0

    JNJ is 2.8 times ARDT

  • Dividend yield

    ARDT0.0%

    JNJ2.0%

    2.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ARDT+66.7%

JNJ+36.6%

100150200DecFebAprJunAugOct
Returns by period
PeriodARDTWith dividendsJNJWith dividends
1 year since November 18, 2025+66.7%Price +66.7%+36.6%Price +33.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ARDTArdent HealthJNJJohnson & Johnson

Valuation

ARDTJNJ
Valuation
Price$14.50$267.14
Market value$2.1B$644B
Enterprise value (EV)$2.4B$671B
P/E14.240.0
P/E, 5-year median–21.9
P/B1.57.9
EV/EBIT8.337.8
Free cash flow yield–3.2%

Results and growth

ARDTJNJ
Results and growth
Revenue, 12 months$6.5B$99.3B
Net income, 12 months$146M$16.1B
Free cash flow, 12 months–$20.6B
Earnings per share, 12 months$1.03$6.59
Revenue growth, year on year6.0%6.1%
Revenue growth a year, past+7.2%over 3 years+2.7%over 5 years
EPS growth a year, past-13.8%over 3 years+14.9%over 5 years

Margins and returns on capital

ARDTJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin––
Net margin2.3%16.2%
ROIC9.5%12.4%
ROE11.1%19.7%

Balance sheet

ARDTJNJ
Balance sheet
Cash$766M$17.2B
Total debt$1.1B$44.7B
Net debt / EBITDA0.71.1
Interest cover–18.0×

Dividends and buybacks

ARDTJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ARDT or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Ardent Health or Johnson & Johnson?

By market value, Johnson & Johnson ($644B) is about 310.7 times Ardent Health ($2.1B), at today's prices.

How did ARDT and JNJ stock do over the last 1 years?

Since November 18, 2025, ARDT's price moved +66.7% and JNJ's +33.6%. With dividends: ARDT +66.7% (+66.7% a year), JNJ +36.6% (+36.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, ARDT or JNJ?

The dividend yield at today's price is none for Ardent Health and 1.98% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of ARDT and JNJ?

At today's price, the P/E is 14.2 for ARDT and 40.0 for JNJ. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Ardent Health or Johnson & Johnson?

Over the last twelve months, the net margin was 2.3% for Ardent Health and 16.2% for Johnson & Johnson, and the operating margin – and –. Revenue was $6.5B and $99.3B.

Which is the better investment, Ardent Health or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.